Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.

Saved in:
Bibliographic Details
Title: Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.
Authors: Cheloni G; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Karagkouni D; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Pita-Juarez Y; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Torres D; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA., Kanata E; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Liegel J; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Avigan Z; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA., Saldarriaga I; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Chedid G; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Rallis K; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Miles B; Kite, a Gilead Company, Santa Monica, CA, USA., Tiwari G; Kite, a Gilead Company, Santa Monica, CA, USA., Kim J; Kite, a Gilead Company, Santa Monica, CA, USA., Mattie M; Kite, a Gilead Company, Santa Monica, CA, USA., Rosenblatt J; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Vlachos IS; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Spatial Technologies Unit, Harvard Medical School Initiative for RNA Medicine, Boston, MA, USA., Avigan D; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. davigan@bidmc.harvard.edu.; Cancer Center, Beth Israel Deaconess Medical Center, Boston, MA, USA. davigan@bidmc.harvard.edu.; Harvard Medical School, Boston, MA, USA. davigan@bidmc.harvard.edu.
Source: Nature communications [Nat Commun] 2025 May 23; Vol. 16 (1), pp. 4819. Date of Electronic Publication: 2025 May 23.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-025-59904-x